Clinical trial

Benefit and Tolerability of IQP-AE-103 in Weight Loss

NCT03058367

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DIETARY_SUPPLEMENT · Unmapped registry intervention IQP-AE-103 (330mg) Find medicine records · Find other trials using this name

DIETARY_SUPPLEMENT · Unmapped registry intervention IQP-AE-103 (165mg) Find medicine records · Find other trials using this name

DIETARY_SUPPLEMENT · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Benefit and Tolerability of IQP-AE-103 in Weight Loss

Design: INTERVENTIONAL · Status: COMPLETED · Phase: NA

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-05-01

PhaseNA

Conditions

Overweightunresolved

Obesityverified · MONDO: obesity disorder

Interventions

IQP-AE-103 (330mg)DIETARY_SUPPLEMENT

IQP-AE-103 (165mg)DIETARY_SUPPLEMENT

PlaceboDIETARY_SUPPLEMENT

Sponsors & collaborators

InQpharm Grouplead sponsor

Mapped research locations

BerlinGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03058367 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.